Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi b.v. - laronidase - mucopolysaccharidose i - andre alimentary tract and metabolism produkter, - aldurazyme er angivet for en langsigtet enzymsubstitutionsbehandlingen i patienter med en bekræftet diagnose på mucopolysaccharidosis jeg (mps jeg; alfa-l-iduronidase mangel) til at behandle nonneurological manifestationer af sygdommen.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

biomarin international limited - galsulfase - mucopolysaccharidose vi - andre alimentary tract and metabolism produkter, - naglazyme er indiceret til langsigtet enzym-substitutionsterapi hos patienter med en bekræftet diagnose af mucopolysaccharidosis vi (mps vi; n-acetylgalactosamine-4-sulfatase mangel; maroteaux-lamy syndrom) (se afsnit 5. som for alle lysosomal genetiske sygdomme, er det af afgørende betydning, især i svære former, til at påbegynde behandling så tidligt som muligt, før fremkomsten af ikke-reversible kliniske manifestationer af sygdommen. et centralt problem er at behandle unge patienter i alderen.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - idursulfase - mucopolysaccharidosis ii - andre alimentary tract and metabolism produkter, - elaprase er indiceret til langtidsbehandling af patienter med hunters syndrom (mucopolysaccharidosis ii, mps ii). heterozygote kvinder blev ikke undersøgt i de kliniske forsøg.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

ultragenyx germany gmbh - vestronidase alfa - mucopolysaccharidosis vii - enzymer - mepsevii er indiceret til behandling af ikke-neurologiske manifestationer af mucopolysaccharidosis vii (mps vii; sly syndrom).

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

viatris aps - danaparoidnatrium - injektionsvæske, opløsning - 750 anti-xa ie/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

leo pharma a/s - tralokinumab - dermatitis, atopisk - andre dermatologiske præparater - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

leo pharma a/s - tacrolimus - dermatitis, atopisk - andre dermatologiske præparater - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. der forekommer fire eller flere gange om året), der har haft en indledende reaktion på højst seks uger behandling af to gange dagligt tacrolimus salve (læsioner ryddet, næsten ryddet eller let påvirket).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astellas pharma gmbh - tacrolimus - dermatitis, atopisk - andre dermatologiske præparater - behandling af moderat til alvorlig atopisk dermatitis hos voksne, som ikke er tilstrækkeligt lydhør overfor eller er intolerante over for konventionelle terapier som topisk kortikosteroider. behandling af moderat til alvorlig atopisk dermatitis hos børn (2 år og derover), som ikke svarede tilstrækkeligt på konventionelle terapier som topiske kortikosteroider. vedligeholdelse behandling af moderat til svær atopisk dermatitis for forebyggelse af nødblus og forlængelse af flare-gratis intervaller i patienter, der oplever en høj frekvens af sygdom eksacerbationer (jeg. forekommer 4 eller flere gange om året), der har haft et første respons på maksimalt 6 uger behandling af to gange daglig tacrolimus salve (læsioner ryddet, næsten ryddet eller mildt ramt).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - midler til dermatitis, undtagen kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig  - crisaborole - dermatitis, atopisk - andre dermatologiske præparater - staquis er indiceret til behandling af mild til moderat atopisk dermatitis hos voksne og pædiatriske patienter fra 2 år med ≤ 40% legemsoverflade (bsa), der berøres.